Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck KGaA establishes joint agreement to market Erbitux in Japan

Merck KGaA establishes joint agreement to market Erbitux in Japan

18th October 2007

Merck KGaA has announced a joint agreement with ImClone Systems and Bristol-Myers Squibb (BMS) to co-develop and co-commercialise Erbitux (cetuximab) in Japan.

The agreement will see the three pharmaceutical companies collaborate to market Erbitux in Japan for the treatment of epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC).

Dr Wolfgang Wein, senior executive vice president of oncology at Merck Serono, confirmed his delight following the agreement.

“This agreement will ensure we can provide Japanese patients with a new important treatment option for metastatic colorectal cancer as soon as our application to the regulatory authorities is approved.”
Merck and BMS hope to use their sales force in Japan while the three companies will share profits and losses gained as a result of the agreement.

Merck Serono Japan will distribute the product and record the sales for the collaboration.

A mutual application for the use of Erbitux in treating patients with EGFR-expressing mCRC in Japan was delivered earlier this year following a development collaboration between the three companies.

Earlier this month, Merck completed the sale of its generics business to Mylan for the total sum of 4.9 billion euros (3.4 billion pounds).

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.